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ABSTRACT
Background: Methods for determining cost-
effectiveness of different treatments are well
established, unlike appraisal of non-drug interventions,
including novel diagnostics and biomarkers.
Objective: The authors develop and validate a new
health economic model by comparing cost-
effectiveness of tuberculin skin test (TST); blood test,
interferon-gamma release assay (IGRA) and TST
followed by IGRA in conditional sequence, in screening
healthcare workers for latent or active tuberculosis (TB).
Design: The authors focus on healthy life years gained
as the beneﬁt metric, rather than quality-adjusted life
years given limited data to estimate quality
adjustments of life years with TB and complications of
treatment, like hepatitis. Healthy life years gained refer
to the number of TB or hepatitis cases avoided and the
increase in life expectancy. The authors incorporate
disease and test parameters informed by systematic
meta-analyses and clinical practice. Health and
economic outcomes of each strategy are modelled as
a decision tree in Markov chains, representing different
health states informed by epidemiology. Cost and
effectiveness values are generated as the individual is
cycled through 20 years of the model. Key parameters
undergo one-way and Monte Carlo probabilistic
sensitivity analyses.
Setting: Screening healthcare workers in secondary
and tertiary care.
Results: IGRA is the most effective strategy, with
incremental costs per healthy life year gained of
£10614e£20929, base case, £8021e£18348, market
costs TST £45, IGRA £90, IGRA speciﬁcities of 99%e
97%; mean (5%, 95%), £12060 (£4137e£38418) by
Monte Carlo analysis.
Conclusions: Incremental costs per healthy life year
gained, a conservative estimate of beneﬁt, are
comparable to the £20000e£30000 NICE band for
IGRA alone, across wide differences in disease and
test parameters. Health gains justify IGRA costs, even
if IGRA tests cost three times TST. This health
economic model offers a powerful tool for appraising
non-drug interventions in the market and under
development.
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ARTICLE SUMMARY
Article focus
- Methods for determining cost-effectiveness of
different treatments are well established unlike
the appraisal of non-drug interventions, including
novel diagnostics and biomarkers.
- We develop and validate a new health economic
model by comparing cost-effectiveness of tuber-
culin skin test (TST) and/or a tuberculosis (TB)
blood test, interferon-gamma release assay
(IGRA), in screening healthcare workers for
latent or active TB.
- We investigate gains in healthy life years, without
TB or hepatitis, in a comprehensive model
informed by epidemiology, meta-analysis and
clinical practice, testing disease and test param-
eters by one-way and Monte Carlo probabilistic
sensitivity analyses.
Key messages
- IGRA is the most effective strategy when
screening healthcare workers for latent or
active TB.
- IGRA screening has an incremental cost per
healthy life year gained of £10614e£20929,
base case, £8021e£18348, market costs, TST
£45, IGRA £90, IGRA speciﬁcities 99%e97%;
mean (5%, 95%), £12060 (£4137e£38418) by
Monte Carlo analysis.
Strengths and limitations of this study
- Screening with IGRA alone appears cost-effective
since incremental costs per healthy life year
gained, a conservative estimate of beneﬁt, are at
the lower end of the £20000e£30000 NICE
band.
- Neither TST nor IGRA differentiate latent from
active TB, and the speciﬁcity of IGRA is inferred
from studies in populations at low risk of TB.
- These ﬁndings are robust for wide differences in
disease and test parameters, such as if IGRA test
costs are three times TST costs, suggesting that
this health economic model is a powerful tool for
appraising non-drug interventions in the market
and under development.
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Open Access ResearchINTRODUCTION
Economic evaluation is a recognised approach to opti-
mising national healthcare provision within a limited
budget, but informed choice requires transparent anal-
ysis highlighting key assumptions and critical factors.
1
Methods for determining the cost-effectiveness of
different treatments are well established,
23unlike the
appraisal of non-drug interventions, including novel
diagnostics and biomarkers. We develop and validate
a new health economic model by focusing on whether
a tuberculin skin test (TST) and/or a blood test for
tuberculosis (TB), interferon-gamma release assay
(IGRA), is more cost-effective in screening healthcare
workers for latent or active TB. The screening of
healthcare workers for TB has economic importance
given the impact of disease transmission in each case
together with the large number of NHS employees at
risk, 1.7 million personnel and 80000 new employees
per annum (NHS, 2010). We inform the health
economic model by applying insight from epidemiology,
meta-analysis and clinical practice including knowledge
of market costs to compare the cost-effectiveness of new
technology supporting or replacing established practice.
The analysis is from the NHS and societal perspective.
Established practice is for trained occupational health
staff to administer a TST using cheap readily available
reagents injected intradermally at an initial visit. The
skin test reaction is measured at a second clinic visit
48e72 h later.
4 The need for two visits is operationally
inefﬁcient, and the test itself is limited both by speciﬁcity
and sensitivity. TST has a low speciﬁcity in subjects
exposed to BCG vaccination or environmental non-
tuberculous mycobacteria (NTM) and moderate sensi-
tivity resulting in false negatives.
56A new technological
approach requires a single clinic visit to draw a blood
sample which is transferred to the laboratory for analysis
in a TB-speciﬁc IGRA.
7 The approach is operationally
efﬁcient, and the assay has a high speciﬁcity and sensi-
tivity, although simple costs per test are greater than the
TST. In principle, the advantages of old and new might
be combined using TST for all and then applying IGRA
blood testing to TST-positive cases to exclude false-posi-
tive TST after previous exposure to NTM including BCG
immunisation. Following earlier work,
8 this study has
focused on healthy life years gained as the beneﬁt
metric, rather than quality-adjusted life years (QALYs).
The reason is the lack of robust data to estimate quality
adjustments of life years with TB and complications of
treatment such as hepatitis. Healthy life years gained
refers to the number of TB or hepatitis cases avoided
and the associated increase in life expectancy.
This study adds to the literature
8e11 in four key areas
by incorporating:
< healthy life years to avoid the assumptions inherent in
estimating QALYs;
< key disease parameters in a comprehensive model of
all relevant health states informed by epidemiology
including
– the impact of side effects from treatment of latent
tuberculosis infection (LTBI) and TB and
12
– the higher relapse rate of active TB within the ﬁrst
3 years of treatment in comparison to the years
thereafter;
13
< key test parameters relevant to clinical practice
including
– the inability of screening tests to differentiate
between active and latent TB,
6
– the sensitivity and speciﬁcity of IGRA and TST
independently of each other and
– operational inefﬁciencies of TST prompting repeat
testing;
14
< and we provide a powerful methodology for
appraising the cost-effectiveness of non-drug inter-
ventions to inform healthcare policy, including
sensitivity analyses of key parameters.
METHODS
The health and economic outcomes of the three alter-
native testing strategies are modelled as a decision
tree, representing the health outcomes of each of the
strategies as Markov chains over 20 years. The model
incorporates economic, medical, epidemiological and
operational factors in the analysis. This approach lends
itself to the clinical setting where the risks are contin-
uous over time, key events may be repeated and opera-
tional factors may interact with other key parameters to
inﬂuence the base case result.
Data collection
The test, population and outcome characteristics
(table 1) include data from the meta-analyses by Menzies
et al
15 and Pai et al.
5 In the absence of a gold standard for
LTBI, active TB is used as a surrogate to determine assay
sensitivity.
15 Speciﬁcity for LTBI is derived by testing
populations at low risk of TB
51 62 0to determine the rate
of false positives. The analysis is guided by our clinical
and market experience with the T-Spot TB test, applying
an IGRA speciﬁcity of 98%
16 for the base case. We then
examine the impact of IGRA speciﬁcity in the sensitivity
analyses of the cost-effectiveness model. The operational
characteristics of the three alternative approaches
include repeat test rates due to test failure and failure to
attend for skin test reading. Direct and indirect costs are
shown (table 2) drawing on data supplied by NICE
21 (see
appendix 6), the Cambridge TB service and the NHS
National tariff 2010
22 with costs adjusted to the
2010e2011 ﬁnancial year (supplementary table 1). The
impact of regional or national differences in disease
parameters and costs are examined in one-way-sensitivity
analyses. The impact of uncertainty within multiple
parameters is then examined using Monte Carlo proba-
bilistic sensitivity analysis.
Model construction
We built a decision analysis model, which incorporates
the health outcomes as Markov chains over 20 years, to
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This model only considers the initial screening for newly
hired personnel; the annual testing is beyond the scope
of this model. The model is coded and composed using
the decision analysis software TreeAge Pro Suite 2009,
2011. The states of the Markov chains represent the
health conditions of the individuals, following a LTBI
diagnosis test and possible interventions. Each Markov
Table 1 Base case data for test, population and outcomes parameters
Parameter Base case values Range tested Reference
1. Test characteristics
TST
Speciﬁcity 0.66 0.46e0.86 15
Sensitivity 0.70 0.65e0.74 15
Probability a second TST is placed 0.1737 0.025e0.25* 14
TB-speciﬁc IGRA
Speciﬁcity 0.98 0.90e0.99 16
Sensitivity 0.90 0.82e0.98 5
Probability a second IGRA is required 0.0343 0.015e0.15* 14
2. Population characteristics
Age range 20e30
Occupation Healthcare worker
BCG vaccination rates 52.8% 17
Nationality of majority English
Prevalence of LTBI 0.035 0.035e0.35* 17
Prevalence of TB 0.0001 0.0001e0.001* 18
Probability of all causes of death 0.0045 0.0045e0.045* Ofﬁce for National
Statistics 2008
3. Probability of outcomes
Efﬁcacy of LTBI treatment 0.65 19
Risk of hepatitis caused by treatment 0.0177 0.0177e0.177* 12
Risk of activation of LTBI 0.01 6
Probability of relapse of TB 0.0315 0.0315e0.315* 13
Probability of death due to TB 0.018 0.018e0.18* 18
Probability of death due to hepatitis 0 Assumption
*10-fold range tested in sensitivity analyses to highlight potential impact on incremental cost per healthy life year gained.
IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test.
Table 2 Costs
Parameter Base case values Range tested
1. Cost of interventions NICE
21
TST £16 £16e£64
IGRA £44.78 £30e£120
Chest radiograph £28
Cambridge TB Service 2010
NHS National Tariff
22
TB treatment £1637 0.5e2 times
Contact tracing £426 0.5e2 times
LTBI treatment £647 0.5e2 times
Hepatitis treatment £640 0.5e2 times
2. Healthcare worker costs Cambridge TB Service 2010
NHS Pay 2/2010
23
Time to attend for TB treatment £662 0.5e2 times
Time to attend for contact tracing £95 0.5e2 times
Time to attend for LTBI treatment £172 0.5e2 times
Time for hepatitis treatment £114 0.5e2 times
3. Discount rate 0.05
TB treatment costs are derived from the NHS National Tariff 2010e2011
22 applied to the Cambridge TB service. Healthcare worker costs are
derived from the NHS Pay Circular (AforC) 2/2010,
23 point 26 £30460, plus 22% overheads £37161 per annum, applied to the Cambridge TB
service. Total model costs for TB treatment are TB treatment, plus contact tracing 35 contacts per case,
19 plus healthcare worker time costs,
£4908; for LTBI, LTBI treatment plus healthcare worker time costs, £819 and for hepatitis, hepatitis treatment plus healthcare worker time costs,
£755 (supplementary table 1).
IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test.
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Screening for TB: development and validation of a new health economic modelstate length is 1 year. The decision is made at the ﬁrst
node of the decision tree between three diagnosis
options: TST, IGRA and a combined sequential testing
strategy. The alternatives are assessed according to their
cost and effectiveness values over 20 years, in which the
costs are direct and indirect monetary costs and their
effectiveness is measured by total number of healthy
years. The Markov chain is implemented through
20 years; related cost and effectiveness values due to
different health states are recorded as the individual is
cycled through the model. All future costs are
discounted at 5% per year. This Markov model assumes
the following
1. Each health state is taken as a time period of 1 year,
cannot be left earlier and can only last longer if the
return probability is greater than zero.
2. All patients with positive results for LTBI accept
treatment, consistent with conditions of employment
in the NHS. The impact of limited compliance is
allowed for within the efﬁcacy of LTBI treatment.
19
3. Standard isoniazid and rifampicin treatment for LTBI
lasts 3 months and all treatments are completed.
4. Diagnostic tests are repeated once only as required to
achieve a result.
5. The repeat rate for diagnostic tests is further
addressed in the sensitivity analyses.
6. The probability that LTBI generates a positive result
is assumed to be the same as the probability that
active TB generates a positive result, as there is no
gold standard for LTBI.
7. The risk of active TB in cases with false-negative
results is proportional to the prevalence rates of
latent and active TB.
8. The result of the second test is independent of the
ﬁrst in two-stage testing.
9. The effects of TB and Hepatitis are the simple sum,
rather than synergistic.
10. All cases with positive TST or IGRA will have a chest
radiograph that identiﬁes all cases of active TB. All
positive chest radiographs are active TB.
11. The relapse rate of TB is higher than the prevalence
rate in the general population for the ﬁrst 3 years
after recovery.
13
12. The probability of continuing to have TB after
standard TB treatment is the probability of relapse.
13. All TB is diagnosed and treated on time. The effect
of late diagnosis of latent or active TB in cases with
false-negative results is neglected.
14. An equal number of males and females make up new
NHS healthcare workers.
15. Death of an employee has no monetary cost for NHS.
16. Transmission of TB to the community is modelled as
a constant monetary cost for contact tracing,
including screening the close contacts of the patient
and their treatment in the case of positive TB ﬁndings.
17. All employees are employed for 20 years.
The comprehensive decision tree consists of 985 nodes
including three similar sub-trees with different proba-
bility and cost parameters (ﬁgure 1). The initial analysis
was then subjected to one-way sensitivity analyses applied
to key parameters including IGRA sensitivity and speci-
ﬁcity; prevalence rates of TB and LTBI; all-cause death
rates; test repetition rates; market rates for TST and
IGRA tests and treatment costs for TB, LTBI and hepa-
titis. We tested the impact of variation in multiple
parameters by ﬁrst generating triangular distributions
using minimum, mode or peak and maximum values for
key parameters.
24 Probabilistic sensitivity analysis was
then carried out by Monte Carlo simulation using
100000 iterations to estimate the total impact of uncer-
tainty on the model, TreeAge Pro 2011.
RESULTS
Base case analysis indicates that the incremental cost of
IGRA alone is offset by the increased effectiveness of this
approach over the two-stage sequential approach of TST
followed by IGRA for positive TST results (table 3a).
IGRA is the most effective strategy with an incremental
effectiveness of 0.0015 and an incremental cost-effec-
tiveness ratio (ICER) of £15757 per healthy life year
gained. The strategy of TSTalone is clearly inferior by all
criteria. We therefore focused on further analysis of
parameters affecting the relative efﬁcacy of TST + IGRA
versus IGRA alone.
Sensitivity analyses of disease and test parameters
Sensitivity analysis of the base case model indicates that
the ICER for IGRA ranges from £20929 to £10614
per healthy life year gained for test speciﬁcities of
97%e99% (ﬁgure 2AeC, supplementary table 2). Assay
sensitivity has a much smaller impact on the ICER
(ﬁgure 2D).
The superior cost-effectiveness of IGRA was not
threatened when base case values were inﬂated 10-fold
for all-cause death rates, TB death rates, prevalence of
LTBI or TB, relapse rates and hepatitis rates (ﬁgure 2E,
supplementary table 3aef).
TST repeat rates were estimated using the 17.4% rate
of failure to achieve a TSTresult in a UK study of routine
practice.
14 This compares with 53%, 35/66, of medical
students who failed to attend their ﬁrst Mantoux
appointment
25 and a 12% failure rate to read the ﬁrst
TST.
11 Varying the IGRA repeat rate from 1.5% to 15%
or TST repeat rate from 2.5% to 25% had little impact
on the ICER which increased from £15573 to £16860
and £14242 to £16776 per healthy life year gained,
respectively (supplementary table 3g, h).
The cost of TST testing was investigated by eliciting costs
from ﬁve private medical service providers, median £65
per test, range £45e£75, and by using estimated itemised
costs from Occupational Health and Safety Service,
University of Cambridge (supplementary, table 1V), total
cost £48.53. We used £45 as a market cost for TST and
tested the impact of test costs on ICER. Market costs for
TSTsigniﬁcantly enhance the ICER for IGRA alone across
a range of IGRA costs (ﬁgure 2F, supplementary table 4).
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TST and £90 per IGRA generate an ICER of £13173 per
healthy life year gained (table 3b). A threshold value of
£30000 per healthy life year gained is still achieved when
IGRA test costs are three times TST test costs.
Examining the impact of assay speciﬁcity and sensi-
tivity, this market standard model generates a range of
£18348e£8021 per healthy life year gained for an IGRA
speciﬁcity of 97%e99%. Sensitivity analysis for TST test
characteristics over a range of 0.46e0.86 for speciﬁcity
and 0.65e0.74 for sensitivity
15 suggests that IGRA
remains the optimal strategy with costs of £354e£31069
and £10385e£16484 per healthy life year gained,
respectively (supplementary table 5).
The calculation and apportionment of treatment costs
is likely to vary between centres, but a fourfold variation,
0.5e2 times baseline, in treatment costs for LTBI, TB or
hepatitis is also accommodated by the market standard
model (ﬁgure 2G, supplementary table 6).
Probabilistic sensitivity analysis by Monte Carlo simu-
lation was carried out with uncertainty in each of 12 key
parameters deﬁned as triangular distributions (supple-
mentary table 7). Mean incremental cost per healthy life
year gained was £12060, with 5% and 95% values of
£4137 and £38418, respectively.
DISCUSSION
The methodology for determining the cost-effectiveness
of different treatments is well established
1e3 in contrast
to the analysis of non-drug interventions. Our health
economic model suggests a methodology to appraise the
host of novel diagnostics
7 and biomarkers generated by
clinical science. Healthy life years, despite being
a conservative beneﬁt metric, may be particularly useful
in evaluating novel screening and monitoring tests by
avoiding the assumptions inherent in generating
QALYs.
1 8 11 26 27 This approach, allied to the use of
multiple disease states supported by epidemiological
Figure 1 The decision tree. Health and economic outcomes of tuberculin skin test and/or IGRA modelled as a decision tree in
Markov chains representing different health states informed by epidemiology: TB, active tuberculosis; LTBI, LTBI1, latent
tuberculosis, with treatment; D, Death; S, S1, healthy, with unnecessary treatment for LTBI; H, H + TB, H + LTBI, hepatitis and TB
or LTBI; T1, T2, T1H, T2H, transition states indicating relapse rates within 3 years of treatment and thereafter, with hepatitis; AeE,
node points repeated as Clones AeE. X, Y are probabilities, p, X ¼ pLTBI/(pLTBI + pTB), Y ¼ pTB/(pLTBI + pTB).
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since the IGRA strategy will overcome a twofold to
threefold excess of simple test costs.
In our study, we compare the effectiveness of the
diagnostic procedures by focusing on healthy life years
gained,
1 8 rather than QALYs.
11 21 26 The reason is there
are limited data to base estimates of QALYs for each of
the health states applicable to latent or active TB and its
treatment.
28 The additional costs of IGRA alone appear
justiﬁed by the health gains at £15757 per healthy life
year gained, falling to £13173 per healthy life year when
applying market costs where blood tests cost twice as
much as skin tests. Our estimates are conservative in that
they only take a healthy life year as a beneﬁt (ie, years
without TB or hepatitis). Since the calculated ratio is at
the lower end of the NICE band of £20000e£30000,
IGRA is cost-effective, even at the current NICE
threshold which may or may not be conservative.
23
These ﬁndings are supported by the probabilistic sensi-
tivity analysis of multiple disease and test parameters.
There is no validated instrument for determining quality
of life with TB,
29 but when such data are available, it is
likely that additional health gains would be identiﬁed,
further improving the cost/beneﬁt ratio.
The health economic model is sensitive to IGRA
speciﬁcity, which is derived from estimates of false
positives in populations at low risk of TB.
16 27 30 An
IGRA speciﬁcity of 98% is conservative by current
literature
16 27 30 but higher than analyses potentially
confounded by data from studies in populations at
intermediate rather than low risk of TB.
52 02 1Our model
accommodates substantial enhancement of TST
speciﬁcity greater than expected in BCG-vaccinated
populations or mixed populations including non-
BCG-vaccinated healthcare workers.
15 The outcome may
be different in non-BCG-vaccinated populations with low
NTM infection rates,
5 but NTM infection is an
increasing problem in adults.
31 Studies testing children
prior to BCG immunisation have revealed false-positive
TST rates of 14% in South East England
32 and 79%
in Norway.
33 It seems likely therefore that previous
infection with NTM has a signiﬁcant role in reducing the
speciﬁc of TST. The study’s ﬁndings accommodate wide
regional or national differences in disease parameters,
although health gains are enhanced by a relative
increase in the prevalence of LTBI and hampered by
doubling costs for the treatment of LTBI.
Studies including the RR of progression to active TB
suggest additional limits to TST speciﬁcity, reviewed
recently.
34 IGRA-positive cases with LTBI are more likely
to progress to active TB than TST-positive cases. In
particular, IGRA-positive cases showed a 19% greater
chance of progression to active TB than expected solely
from the increased speciﬁcity of IGRA over TST.
10
This advantage would lead to further domination of TST-
only approaches, by sequential TST then IGRA and
IGRA-alone strategies.
The one-stop approach of IGRA alone has additional
operational advantages, which are likely to enhance the
value of this strategy. Testing at a single visit boosts
compliance while minimising consumption of resources
to achieve a test result and the risk of loss to follow-up.
The health economic model does not include an allow-
ance for healthcare workers’ time to attend for testing,
but these staff costs would be greater when two to three
visits are required for TST then IGRA further limiting
cost-effectiveness of strategies incorporating TST. Efﬁ-
ciency is enhanced by combining IGRA with other
screening blood tests, although a blood sample is more
invasive than TST. Blood testing may offer more ﬂexi-
bility than TST with blood sampling facilities widely
available in primary care and hospital settings. In
contrast, carrying out a TST requires registered nurses
with proven competence and recent training or admin-
istration of TSTs,
4 which is more expensive than phle-
botomy and may be limiting during peaks in demand
such as in contact tracing. An IGRA strategy transfers
costs from the clinic to the laboratory, where cost pres-
sures are intense but responsive to focusing expertise
and optimising stafﬁng structures. Critical aspects of
blood sampling are deﬁned including the impact of the
test population and sampling conditions on the perfor-
mance characteristics of IGRA.
14 35e37 An IGRA strategy
also avoids the possibility of TST boosting TSTresponses
Table 3 Incremental costs per healthy life year gained (ICER) of IGRA or TST
Strategy Cost Incremental cost Effectiveness
Incremental
effectiveness Cost/effectiveness ICER
a. Base case
IGRA + TST £76.60 £0.00 19.07569 0 4.02 £0
IGRA £99.52 £22.92 19.07714 0.001455 5.22 £15757
TST £333.42 £233.90 19.07088  0.00626 17.48  £37358
(Dominated)
b. Market costs
IGRA + TST £127.13 £0.00 19.0757 0 6.66 £0
IGRA £146.29 £19.16 19.0771 0.00145 7.67 £13173
TST £367.45 £221.16 19.0709  0.0063 19.27  £35324
(Dominated)
Base case, TST £16, IGRA £45; market costs TST £45, IGRA £90.
ICER, incremental cost-effectiveness ratio; IGRA, interferon-gamma release assay; TST, tuberculin skin test.
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6 or IGRA responses if follow-up
testing is delayed.
36 The relative merits of different IGRA
tests are controversial,
51 62 7but where there is
a consensus on the assay characteristics, this model
should allow further investigation.
Our study suggests that health gains justify IGRA costs
when screening healthcare workers for latent or active
TB. These ﬁndings are robust for wide differences in key
disease and test parameters, such as if IGRA test costs are
three times TST costs, while maintaining cost-effective-
ness at the lower end of the £20000e£30000 NICE
band. We suggest that this health economic model
incorporating healthy life years gained, epidemiology,
meta-analyses and clinical practice provides a powerful
tool for assessing the potential impact of new technology
on established practice.
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